Breaking News

Financial Report: AbbVie

February 1, 2016

Humira revenues up 11% in the quarter

4Q Revenues: $6.4 billion (+17%)

4Q Earnings: $1.5 billion (loss of $810 million 4Q14)

FY Revenues: $22.9 billion (+15%)

FY Earnings: $5.1 billion (+190%)

Comments: Humira revenues were $3.7 billion in the quarter, up 11%. Growth in the quarter was also driven by Imbruvica sales of $343 million, Viekira sales of $554 million, and Creon sales of $185 million. Lupron sales were $235 million, up 13%. Synagis sales were down 11% to $266 million. Kaletra sales were down 9% to $185 million. AndroGel sales were down 16% to $194 million. 2014 earnings were impacted by the Shire termination.
  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks